XML 75 R48.htm IDEA: XBRL DOCUMENT
v3.24.1.u1

Note 4 - Collaboration Revenue - Schedule of Collaboration Revenue (Details) - USD ($) $ in Thousands |  | 1 Months Ended | 12 Months Ended
--- | --- | --- | ---
Nov. 20, 2020 | Nov. 30, 2020 | Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020
Fair value of Series A-2 Preferred Shares (Note 14) |  |  | $ 0 | $ 5,000 | $ 0 |
SEED Therapeutics Inc. [Member] | Research Collaboration and License Agreement with Eli Lilly [Member] |  |  |  |  |  |
Collaboration arrangement – research and development services | $ 9,455 | $ 10,000 |  |  |  |
Fair value of Series A-2 Preferred Shares (Note 14) | 5,267 |  |  |  |  |
Fair value of the Forward (Note 15) | 278 |  |  |  |  |
Total cash proceeds | $ 15,000 |  |  |  |  | $ 15,000

X
- Definition The amount of upfront cash payment from collaborative arrangement. + References No definition available. + Details
Name: | bysi_CollaborativeArrangementUpfrontCashPayment
Namespace Prefix: | bysi_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Represents the proceeds allocated to forward liability. + References No definition available. + Details
Name: | bysi_ProceedsAllocatedToForwardLiability
Namespace Prefix: | bysi_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The cash inflow from issuance of redeemable noncontrolling interests. + References No definition available. + Details
Name: | bysi_ProceedsFromIssuanceOfRedeemableNoncontrollingInterests
Namespace Prefix: | bysi_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3 + Details
Name: | us-gaap_ProceedsFromIssuanceOrSaleOfEquity
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Details
Name: | dei_LegalEntityAxis=bysi_SEEDTherapeuticsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=bysi_ResearchCollaborationAndLicenseAgreementWithEliLillyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |